COVID-19: Pfizer, BioNTech Claim Experimental Vaccine Shows 95% Effectiveness | Lagos Post Online

COVID-19: Pfizer, BioNTech Claim Experimental Vaccine Shows 95% Effectiveness

Pfizer and BioNTech on Wednesday said a completed study of their experimental COVID-19 vaccine showed it was 95 percent effective.

The two health companies said the two-dose vaccine had no serious safety concerns and that the companies will apply for emergency use authorization from US regulators “within days.”

The announcement came as coronavirus cases are surging in the US and other parts of the world, and boosted hopes for an end to the pandemic that has upended life around the globe.

“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,” said Pfizer CEO Albert Bourla.

“With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world,” he added.

ALSO READ: Facebook Launches Nigerian SMB Success Stories Series

Pfizer had said last week after a preliminary analysis that its product was more than 90 percent effective.

On Monday another biotech firm involved in the race to develop a vaccine, Moderna, said its own vaccine was 94.5 percent effective, according to a preliminary analysis.

Pfizer has previously said it expected to contact the US Food and Drug Administration to apply for an Emergency Use Authorization by the third week of November.

The FDA had imposed a requirement on Covid-19 vaccine makers of having at least two months of follow-up with volunteers after their second dose, taken 28 days after the first, in order to ensure the drugs are safe.

Moderna developed its vaccine along with the US National Institutes for Health.

Both vaccines use mRNA (messenger ribonucleic acid) technology to deliver genetic material to the body that makes human cells create a protein from the virus.

This trains the immune system to be ready to attack if it encounters SARS-CoV-2.

-AFP

Leave a Reply

Your email address will not be published. Required fields are marked *